PYXS Stock Analysis: Buy, Sell, or Hold?
PYXS - Pyxis Oncology, Inc. Common Stock
$2.75
-0.32 (-10.59%)
▼
5d:
-8.8%
30d:
+54.21%
90d:
+88.01%
HOLD
MODERATE Confidence
Analysis Updated: Jul 8, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When PYXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PYXS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PYXS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PYXS is currently trading at $2.75, which is considered extended relative to its 30-day fair value range of $1.66 to $2.62.
Technical Outlook: Technically, PYXS is in a uptrend. The price is approaching resistance at $1.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 10.6% recently.
Market Sentiment: PYXS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.75 (+119.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PYXS is in a uptrend. The price is approaching resistance at $1.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 10.6% recently.
Market Sentiment: PYXS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.75 (+119.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.66 -
$2.62
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.6%)
- BULLISH: Trading 119.9% below Wall St target ($6.75)
- CAUTION: 5-day price weakness (-8.8%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.66 -
$2.62
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.60
Resistance Level
$1.88
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.57
Wall Street Target
$6.75
(+119.9%)
Share & Embed Analysis
Last updated: July 08, 2026 3:27 PM ET
Data refreshes hourly during market hours. Next update: 4:27 PM
Data refreshes hourly during market hours. Next update: 4:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PYXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 54 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
